Recent Insider Transactions • May 11
Chief Financial Officer recently bought kr.622k worth of stock On the 7th of May, Henrik Bender bought around 10k shares on-market at roughly kr.62.20 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Henrik's only on-market trade for the last 12 months. Reported Earnings • May 06
Second quarter 2026 earnings released: EPS: kr.0.46 (vs kr.0.71 in 2Q 2025) Second quarter 2026 results: EPS: kr.0.46 (down from kr.0.71 in 2Q 2025). Revenue: kr.1.57b (up 1.2% from 2Q 2025). Net income: kr.121.0m (down 36% from 2Q 2025). Profit margin: 7.7% (down from 12% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 05
First quarter 2026 earnings released: EPS: kr.0.44 (vs kr.0.68 in 1Q 2025) First quarter 2026 results: EPS: kr.0.44 (down from kr.0.68 in 1Q 2025). Revenue: kr.1.56b (up 3.2% from 1Q 2025). Net income: kr.118.0m (down 36% from 1Q 2025). Profit margin: 7.6% (down from 12% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Upcoming Dividend • Nov 27
Upcoming dividend of kr.0.41 per share Eligible shareholders must have bought the stock before 04 December 2025. Payment date: 08 December 2025. Payout ratio is a comfortable 18% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of British dividend payers (5.6%). Lower than average of industry peers (2.2%). Recent Insider Transactions • Nov 10
Chief Executive Officer recently bought kr.1.6m worth of stock On the 7th of November, Britt Jensen bought around 20k shares on-market at roughly kr.81.60 per share. This transaction amounted to 34% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Britt has been a buyer over the last 12 months, purchasing a net total of kr.3.2m worth in shares. Declared Dividend • Nov 08
Dividend increased to kr.0.41 Dividend of kr.0.41 is 7.9% higher than last year. Ex-date: 4th December 2025 Payment date: 8th December 2025 Dividend yield will be 0.5%, which is lower than the industry average of 2.4%. Payout Ratios Payout ratio: 18%. Cash payout ratio: 27%. Announcement • Nov 07
Ambu A/S announces Annual dividend, payable on December 08, 2025 Ambu A/S announced Annual dividend of DKK 0.4100 per share payable on December 08, 2025, ex-date on December 04, 2025 and record date on December 05, 2025. Reported Earnings • Nov 06
Full year 2025 earnings released: EPS: kr.2.29 (vs kr.0.88 in FY 2024) Full year 2025 results: EPS: kr.2.29 (up from kr.0.88 in FY 2024). Revenue: kr.6.04b (up 12% from FY 2024). Net income: kr.609.0m (up 159% from FY 2024). Profit margin: 10% (up from 4.4% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Nov 05
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to kr.82.60, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 12x in the Medical Equipment industry in the United Kingdom. Total loss to shareholders of 11% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.131 per share. Buy Or Sell Opportunity • Oct 27
Now 21% undervalued Over the last 90 days, the stock has risen 5.5% to kr.106. The fair value is estimated to be kr.134, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 48%. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings are also forecast to grow by 24% per annum over the same time period. Valuation Update With 7 Day Price Move • Oct 07
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to kr.108, the stock trades at a forward P/E ratio of 39x. Average forward P/E is 17x in the Medical Equipment industry in the United Kingdom. Total returns to shareholders of 59% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.138 per share. Announcement • Oct 01
Ambu A/S, Annual General Meeting, Dec 02, 2026 Ambu A/S, Annual General Meeting, Dec 02, 2026. Reported Earnings • Aug 24
Third quarter 2025 earnings released: EPS: kr.0.46 (vs kr.0.50 in 3Q 2024) Third quarter 2025 results: EPS: kr.0.46 (down from kr.0.50 in 3Q 2024). Revenue: kr.1.51b (up 9.0% from 3Q 2024). Net income: kr.123.0m (down 8.2% from 3Q 2024). Profit margin: 8.2% (down from 9.7% in 3Q 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Announcement • Aug 22
Ambu A/S Revises Financial Guidance for the Year 2024/25 Ambu A/S revised financial guidance for the year 2024/25. For the period, the company revised organic revenue growth: 12% to 14% (previously 11% to 14%) and EBIT margin b.s.i.: 13% to 15%. Buy Or Sell Opportunity • Jun 17
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 24% to kr.93.33. The fair value is estimated to be kr.119, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 37%. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 25% per annum over the same time period. Reported Earnings • May 07
Second quarter 2025 earnings released: EPS: kr.0.71 (vs kr.0.54 in 2Q 2024) Second quarter 2025 results: EPS: kr.0.71 (up from kr.0.54 in 2Q 2024). Revenue: kr.1.55b (up 14% from 2Q 2024). Net income: kr.188.0m (up 31% from 2Q 2024). Profit margin: 12% (up from 11% in 2Q 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Board Change • Feb 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. Director David Hale was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Jan 31
First quarter 2025 earnings released: EPS: kr.0.68 (vs kr.0.35 in 1Q 2024) First quarter 2025 results: EPS: kr.0.68 (up from kr.0.35 in 1Q 2024). Revenue: kr.1.51b (up 20% from 1Q 2024). Net income: kr.183.0m (up 99% from 1Q 2024). Profit margin: 12% (up from 7.3% in 1Q 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. New Risk • Jan 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.4% average weekly change). Large one-off items impacting financial results. Buy Or Sell Opportunity • Jan 10
Now 35% overvalued after recent price rise Over the last 90 days, the stock has risen 8.5% to kr.136. The fair value is estimated to be kr.101, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.8% over the last 3 years. Earnings per share has grown by 17%. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings are also forecast to grow by 28% per annum over the same time period. Announcement • Jan 10
Ambu A/S Raises Financial Guidance for the Year 2024/25 Ambu A/S provided financial guidance for the year 2024/25. The outlook for organic revenue growth is set to 11-14% (previously 10-13%) and for EBIT margin before special items to 13-15% (previously 12-14%). Upcoming Dividend • Nov 28
Upcoming dividend of kr.0.38 per share Eligible shareholders must have bought the stock before 05 December 2024. Payment date: 09 December 2024. Payout ratio is a comfortable 43% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (2.6%). Recent Insider Transactions • Nov 26
Chief Executive Officer recently bought kr.1.6m worth of stock On the 22nd of November, Britt Jensen bought around 14k shares on-market at roughly kr.113 per share. This transaction amounted to 31% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Britt's only on-market trade for the last 12 months. Announcement • Nov 08
Ambu A/S Proposes Dividend The Board of Directors of Ambu A/S proposed a dividend of DKK 0.38 per share of nominally DKK 0.50 so that a dividend in the total amount of DKK 102 million be paid out of the net profit for the year, corresponding to 43% of the group's net profit, whereas the remaining part of the net profit be carried forward to next year. Reported Earnings • Nov 05
Full year 2024 earnings released: EPS: kr.0.88 (vs kr.0.65 in FY 2023) Full year 2024 results: EPS: kr.0.88 (up from kr.0.65 in FY 2023). Revenue: kr.5.39b (up 13% from FY 2023). Net income: kr.235.0m (up 40% from FY 2023). Profit margin: 4.4% (up from 3.5% in FY 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Announcement • Sep 30
Ambu A/S to Report Q1, 2025 Results on Jan 30, 2025 Ambu A/S announced that they will report Q1, 2025 results on Jan 30, 2025 Reported Earnings • Aug 31
Third quarter 2024 earnings released: EPS: kr.0.50 (vs kr.0.19 in 3Q 2023) Third quarter 2024 results: EPS: kr.0.50 (up from kr.0.19 in 3Q 2023). Revenue: kr.1.38b (up 16% from 3Q 2023). Net income: kr.134.0m (up 163% from 3Q 2023). Profit margin: 9.7% (up from 4.3% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Reported Earnings • May 15
Second quarter 2024 earnings released: EPS: kr.0.54 (vs kr.0.06 in 2Q 2023) Second quarter 2024 results: EPS: kr.0.54 (up from kr.0.06 in 2Q 2023). Revenue: kr.1.37b (up 15% from 2Q 2023). Net income: kr.144.0m (up kr.129.0m from 2Q 2023). Profit margin: 11% (up from 1.3% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 18% per year and the company’s share price has also fallen by 18% per year. Reported Earnings • Jan 30
First quarter 2024 earnings released First quarter 2024 results: Revenue: kr.1.25b (up 11% from 1Q 2023). Net income: kr.92.0m (up 318% from 1Q 2023). Profit margin: 7.3% (up from 1.9% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in the United Kingdom. Announcement • Dec 14
Ambu A/S Elects Shacey Petrovic as Vice Chair of Board of Directors Ambu A/S at its Annual General Meeting held on December 13, 2023, elected Shacey Petrovic as Vice Chair of the Board of Directors. Announcement • Nov 18
Ambu A/S Announces Henrik Ehlers Wulff Not to Run for Re-Election for Board of Directors Ambu A/S at the Annual General Meeting to be held on 13 December 2023 Henrik Ehlers Wulff has decided not to run for re-election for Board of Directors. Announcement • Nov 09
Ambu A/S Provides Earnings Guidance for the Full-Year 2023/24 Ambu A/S provided earnings guidance for the full-year 2023/24 . For the year, the company expected total organic revenue growth 7-10% for the 2023/24 financial year, compared to 7.6% in 2022/23; EBIT before special items is expected to be 8-10%, compared to 6.3% in 2022/23. Reported Earnings • Sep 01
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: kr.1.20b (up 5.9% from 3Q 2022). Net income: kr.51.0m (up 82% from 3Q 2022). Profit margin: 4.3% (up from 2.5% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in the United Kingdom. Announcement • Jul 12
Ambu A/S Raises Earnings Guidance for the Full-Year 2022/2023 Ambu A/S raised earnings guidance for the full-year 2022/2023. For the year, company expects EBIT margin before special items to 5% - 6% (previously 3% - 5%). Reported Earnings • May 03
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: kr.1.19b (up 6.0% from 2Q 2022). Net income: kr.15.0m (down 91% from 2Q 2022). Profit margin: 1.3% (down from 16% in 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 21% per year whereas the company’s share price has fallen by 19% per year. Reported Earnings • Feb 08
First quarter 2023 earnings released: EPS: kr.0.09 (vs kr.0.08 in 1Q 2022) First quarter 2023 results: EPS: kr.0.09 (up from kr.0.08 in 1Q 2022). Revenue: kr.1.13b (up 9.8% from 1Q 2022). Net income: kr.22.0m (up 10.0% from 1Q 2022). Profit margin: 1.9% (in line with 1Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Announcement • Feb 07
Ambu A/S Provides Earnings Guidance for the Financial Year of 2022-2023 Ambu A/S provided earnings guidance for the financial year of 2022-2023. For the year, the company expected organic revenue growth is 5% to 8%. Board Change • Nov 22
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Susanne Larsson was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 16
Full year 2022 earnings released Full year 2022 results: Revenue: kr.4.44b (up 11% from FY 2021). Net income: kr.93.0m (down 62% from FY 2021). Profit margin: 2.1% (down from 6.2% in FY 2021). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 14% per year. Buying Opportunity • Oct 05
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 7.3%. The fair value is estimated to be kr.84.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has declined by 21%. Revenue is forecast to grow by 26% in 2 years. Earnings is forecast to grow by 79% in the next 2 years. Buying Opportunity • Sep 19
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 12%. The fair value is estimated to be kr.84.26, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has declined by 21%. Revenue is forecast to grow by 26% in 2 years. Earnings is forecast to grow by 74% in the next 2 years. Reported Earnings • Aug 25
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: kr.1.13b (up 16% from 3Q 2021). Net income: kr.28.0m (down 55% from 3Q 2021). Profit margin: 2.5% (down from 6.4% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 16%, compared to a 12% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorated over the past week After last week's 15% share price decline to kr.70.48, the stock trades at a forward P/E ratio of 53x. Average forward P/E is 29x in the Medical Equipment industry in the United Kingdom. Total loss to shareholders of 32% over the past three years. Valuation Update With 7 Day Price Move • Jun 14
Investor sentiment deteriorated over the past week After last week's 19% share price decline to kr.70.25, the stock trades at a forward P/E ratio of 55x. Average forward P/E is 29x in the Medical Equipment industry in the United Kingdom. Total loss to shareholders of 21% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.139 per share. Reported Earnings • May 06
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: kr.1.12b (up 12% from 2Q 2021). Net income: kr.175.0m (up 84% from 2Q 2021). Profit margin: 16% (up from 9.5% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 25%, compared to a 16% growth forecast for the industry in the United Kingdom. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 7 non-independent directors. Independent Director Henrik Wulff was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 09
First quarter 2022 earnings: Revenues and EPS in line with analyst expectations First quarter 2022 results: EPS: kr.0.08 (down from kr.0.37 in 1Q 2021). Revenue: kr.1.03b (up 1.8% from 1Q 2021). Net income: kr.20.0m (down 78% from 1Q 2021). Profit margin: 1.9% (down from 9.0% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 24%, compared to a 15% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Dec 08
Upcoming dividend of kr.0.29 per share Eligible shareholders must have bought the stock before 15 December 2021. Payment date: 17 December 2021. Payout ratio is a comfortable 30% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of British dividend payers (4.1%). Lower than average of industry peers (2.1%). Reported Earnings • Nov 12
Full year 2021 earnings released: EPS kr.0.98 (vs kr.0.98 in FY 2020) The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2021 results: Revenue: kr.4.01b (up 13% from FY 2020). Net income: kr.247.0m (up 2.5% from FY 2020). Profit margin: 6.2% (down from 6.8% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings. Reported Earnings • Aug 18
Third quarter 2021 earnings released The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: kr.973.0m (up 2.7% from 3Q 2020). Net income: kr.62.0m (down 33% from 3Q 2020). Profit margin: 6.4% (down from 9.7% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Reported Earnings • May 13
Second quarter 2021 earnings released The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: kr.1.00b (up 1.2% from 2Q 2020). Net income: kr.95.0m (down 8.7% from 2Q 2020). Profit margin: 9.5% (down from 11% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Feb 12
New 90-day high: kr.329 The company is up 57% from its price of kr.210 on 13 November 2020. The British market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is kr.272 per share. Reported Earnings • Jan 28
First quarter 2021 earnings released The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr.1.01b (up 33% from 1Q 2020). Net income: kr.91.0m (up 117% from 1Q 2020). Profit margin: 9.0% (up from 5.5% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 36% per year, which means it is well ahead of earnings. Analyst Estimate Surprise Post Earnings • Jan 28
Revenue beats expectations Revenue exceeded analyst estimates by 13%. Over the next year, revenue is forecast to grow 14%, compared to a 10% growth forecast for the Medical Equipment industry in the United Kingdom. Is New 90 Day High Low • Jan 27
New 90-day high: kr.301 The company is up 55% from its price of kr.193 on 29 October 2020. The British market is up 20% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is kr.322 per share. Is New 90 Day High Low • Dec 16
New 90-day high: kr.215 The company is up 30% from its price of kr.165 on 17 September 2020. The British market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is kr.64.65 per share. Upcoming Dividend • Dec 03
Upcoming Dividend of kr.0.29 Per Share Will be paid on the 14th of December to those who are registered shareholders by the 10th of December. The trailing yield of 0.1% is below the top quartile of British dividend payers (4.8%), and is lower than industry peers (1.9%). Is New 90 Day High Low • Nov 30
New 90-day high: kr.211 The company is up 20% from its price of kr.176 on 01 September 2020. The British market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is kr.55.43 per share. Analyst Estimate Surprise Post Earnings • Nov 12
Revenue misses expectations Revenue missed analyst estimates by 0.2%. Over the next year, revenue is forecast to grow 17%, compared to a 7.4% growth forecast for the Medical Equipment industry in the United Kingdom.